|
Site of action
|
Agent
|
Human studies
|
|---|
|
Interruption of TCR/MHC
| | |
|
binding
| | |
|
CD4/MHC class II
|
Anti-CD4 mAbs
|
Yes
|
|
Interruption of T cell
| | |
|
co-stimulation
| | |
|
CD28/B7
|
CTLA4-Ig
|
Yes (psoriasis)
|
|
CD40/CD154
|
Anti-ICAM-1 mAbs
|
Yes (ITP)
|
|
Interruption of cell adhesion
| | |
|
LFA-1/ICAM-1
|
Anti-LFA-1 mAbs
|
Yes
|
| |
Anti-ICAM-1 mAbs
|
Yes
|
|
Interruption of accessory
| | |
|
molecule interactions
| | |
|
CD2/LFA-3
|
Anti-LFA-3 mAbs
|
No
|
| |
Anti-CD2 mAbs
|
Yes
|
|
CD45
|
Anti-CD45
|
Yes
|
- ICAM-1, intracellular adhesion molecule-1; ITP, idiopathic thrombocytopenic purpura; LFA, lymphocyte function associated antigen; mAb, monoclonal antibody; MHC, major histocompatibility complex; TCR, T cell receptor.
